Indian drugmaker Sun Pharma along with its subsidiaries and/or associate companies, have executed a definitive agreement to take a majority stake in a Russian company in order to expand its presence in that market.
As a result, Sun Pharma will acquire an 85.1% stake in JSC Biosintez, which is engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. The equity consideration for the 85.1% stake is $24 million.
Sun Pharma would also assume a debt of about $36 million as part of this transaction. Biosintez is a Russian pharmaceutical company focusing on the hospital segment with annual revenues of around $52 million for 2015. It has a manufacturing facility in Penza region with capabilities to manufacture a wide variety of dosage forms including pharmaceuticals for injections, blood substitutes, blood preservatives, ampoules, tablets, ointment, creams, gels, suppositories, APIs, etc.
According to Aalok Shanghvi, head of emerging markets, Sun Pharma:“This acquisition is consistent withSun Pharma’s philosophy to invest in strategic Emerging Markets. This transaction gives us access to localmanufacturing capability across multiple dosage forms in Russia, enabling us to serve the Russia pharmaceuticalmarket more effectively.”
“This is an important milestone for us,” added Artur Valliev, country head at Sun Pharma Russia, saying: “The acquisition signifies Sun Pharma’s commitment to Russia and the Russian 2020 plan for localization.”
The transaction, expected to be completed by end of 2016, is subject to approval of the Russian Federal Anti-Monopoly Service and other closing conditions.
As per IMS (MAT September 2016), the Russian pharmaceutical market recorded sales of approximately $10 billion. The market recorded a growth of 7.4% in local currency terms.
Source: The Pharma Letter
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
